International Journal of Women's Dermatology (Sep 2018)

Pemphigoid gestationis and intravenous immunoglobulin therapy

  • Anes Yang, MD, BMed, MPH,
  • Elizabeth Uhlenhake, MD, FAAD,
  • Dedee F. Murrell, MA, BMBCh, FAAD, MD, FACD, FRCP

Journal volume & issue
Vol. 4, no. 3
pp. 166 – 169

Abstract

Read online

Pemphigoid gestationis, which is also known as herpes gestationis, is a rare, pregnancy-associated, autoimmune bullous disease. Treatment depends on the severity of the disease for each patient and the safety and use of these drugs during pregnancy and breastfeeding must be taken into consideration to guide their use. We describe the therapeutic response of two cases of pemphigoid gestationis that did not respond to conventional immunosuppressive therapy or adverse effects limited their use. Both patients eventually received treatment with intravenous immunoglobulin therapy, which resulted in clinical remission. This clinical improvement with disappearance of lesions and a reduction in pruritus was paralleled in a decline in Bullous Pemphigoid Disease Activity Index activity scores, which is a validated scoring system to measure the related condition, bullous pemphigoid. Keywords: Bullous gestationis, herpes gestationis, BP180, intravenous immunoglobulin, bullous pemphigoid, pregnancy, BPDAI, IVIG